Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer

Abstract

Costlier prostate cancer therapies were rapidly and widely adopted, resulting in additional national spending of more than $350 million among men diagnosed in 2005 and suggesting the need for comparative effectiveness research to weigh their costs against their benefits.